PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Abstract
Authors
M. Erder K. Chen E.Q. Wu P. Hodgkins V. Sikirica